193 related articles for article (PubMed ID: 38388872)
1. Vonoprazan: A Review in Helicobacter pylori Infection.
Shirley M
Drugs; 2024 Mar; 84(3):319-327. PubMed ID: 38388872
[TBL] [Abstract][Full Text] [Related]
2. Treatment of
Kanu JE; Soldera J
World J Gastroenterol; 2024 Mar; 30(9):1213-1223. PubMed ID: 38577188
[TBL] [Abstract][Full Text] [Related]
3. Vonoprazan With Amoxicillin or Amoxicillin and Clarithromycin for the Treatment of
Liu L; Nahata MC
Ann Pharmacother; 2023 Oct; 57(10):1185-1197. PubMed ID: 36688309
[TBL] [Abstract][Full Text] [Related]
4. Vonoprazan Triple and Dual Therapy for Helicobacter pylori Infection in the United States and Europe: Randomized Clinical Trial.
Chey WD; Mégraud F; Laine L; López LJ; Hunt BJ; Howden CW
Gastroenterology; 2022 Sep; 163(3):608-619. PubMed ID: 35679950
[TBL] [Abstract][Full Text] [Related]
5. Helicobacter pylori Eradication with Proton Pump Inhibitors or Potassium-Competitive Acid Blockers: The Effect of Clarithromycin Resistance.
Matsumoto H; Shiotani A; Katsumata R; Fujita M; Nakato R; Murao T; Ishii M; Kamada T; Haruma K; Graham DY
Dig Dis Sci; 2016 Nov; 61(11):3215-3220. PubMed ID: 27659671
[TBL] [Abstract][Full Text] [Related]
6. Vonoprazan versus conventional proton pump inhibitor-based triple therapy as first-line treatment against Helicobacter pylori: A multicenter retrospective study in clinical practice.
Shichijo S; Hirata Y; Niikura R; Hayakawa Y; Yamada A; Mochizuki S; Matsuo K; Isomura Y; Seto M; Suzuki N; Suzuki H; Yamamoto S; Sugimoto T; Omae T; Okamoto M; Watabe H; Togo G; Takano N; Fukui K; Ito Y; Koike K
J Dig Dis; 2016 Oct; 17(10):670-675. PubMed ID: 27534444
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of Vonoprazan for Helicobacter pylori Eradication.
Kiyotoki S; Nishikawa J; Sakaida I
Intern Med; 2020 Jan; 59(2):153-161. PubMed ID: 31243237
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and Safety of Vonoprazan and Amoxicillin Dual Therapy for Helicobacter pylori Eradication: A Systematic Review and Meta-Analysis.
Zhang WL; Lin BS; Li YY; Ding YM; Han ZX; Ji R
Digestion; 2023; 104(4):249-261. PubMed ID: 37015201
[TBL] [Abstract][Full Text] [Related]
9. Vonoprazan, a novel potassium-competitive acid blocker, as a component of first-line and second-line triple therapy for Helicobacter pylori eradication: a phase III, randomised, double-blind study.
Murakami K; Sakurai Y; Shiino M; Funao N; Nishimura A; Asaka M
Gut; 2016 Sep; 65(9):1439-46. PubMed ID: 26935876
[TBL] [Abstract][Full Text] [Related]
10. Clinical trial: seven-day vonoprazan- versus 14-day proton pump inhibitor-based triple therapy for first-line Helicobacter pylori eradication.
Ang D; Koo SH; Chan YH; Tan TY; Soon GH; Tan CK; Lin KW; Krishnasamy-Balasubramanian JK; Wong YJ; Kumar R; R R; Tan Y; Ong PJ; Tan YJ; Li JW; Kwek AB; Ang TL
Aliment Pharmacol Ther; 2022 Aug; 56(3):436-449. PubMed ID: 35665947
[TBL] [Abstract][Full Text] [Related]
11. Vonoprazan-based triple therapy is non-inferior to susceptibility-guided proton pump inhibitor-based triple therapy for Helicobacter pylori eradication.
Tanabe H; Yoshino K; Ando K; Nomura Y; Ohta K; Satoh K; Ichiishi E; Ishizuka A; Otake T; Kohgo Y; Fujiya M; Okumura T
Ann Clin Microbiol Antimicrob; 2018 Jun; 17(1):29. PubMed ID: 29950163
[TBL] [Abstract][Full Text] [Related]
12. Systematic review with meta-analysis: the efficacy of vonoprazan-based triple therapy on Helicobacter pylori eradication.
Jung YS; Kim EH; Park CH
Aliment Pharmacol Ther; 2017 Jul; 46(2):106-114. PubMed ID: 28497487
[TBL] [Abstract][Full Text] [Related]
13. Dual Therapy with Vonoprazan and Amoxicillin Is as Effective as Triple Therapy with Vonoprazan, Amoxicillin and Clarithromycin for Eradication of Helicobacter pylori.
Furuta T; Yamade M; Kagami T; Uotani T; Suzuki T; Higuchi T; Tani S; Hamaya Y; Iwaizumi M; Miyajima H; Umemura K; Osawa S; Sugimoto K
Digestion; 2020; 101(6):743-751. PubMed ID: 31434101
[TBL] [Abstract][Full Text] [Related]
14. Effect of Age on Effectiveness of Vonoprazan in Triple Therapy for Helicobacter pylori Eradication.
Kusunoki M; Yuki M; Ishitobi H; Kobayashi Y; Nagaoka M; Takahashi Y; Fukuba N; Komazawa Y; Shizuku T; Kinoshita Y
Intern Med; 2019 Jun; 58(11):1549-1555. PubMed ID: 30713328
[TBL] [Abstract][Full Text] [Related]
15. Seven-day vonoprazan and low-dose amoxicillin dual therapy as first-line
Suzuki S; Gotoda T; Kusano C; Ikehara H; Ichijima R; Ohyauchi M; Ito H; Kawamura M; Ogata Y; Ohtaka M; Nakahara M; Kawabe K
Gut; 2020 Jun; 69(6):1019-1026. PubMed ID: 31915235
[TBL] [Abstract][Full Text] [Related]
16. Systematic review with meta-analysis: Vonoprazan, a potent acid blocker, is superior to proton-pump inhibitors for eradication of clarithromycin-resistant strains of Helicobacter pylori.
Li M; Oshima T; Horikawa T; Tozawa K; Tomita T; Fukui H; Watari J; Miwa H
Helicobacter; 2018 Aug; 23(4):e12495. PubMed ID: 29873436
[TBL] [Abstract][Full Text] [Related]
17. Eradication rate and safety of a "simplified rescue therapy": 14-day vonoprazan and amoxicillin dual regimen as rescue therapy on treatment of Helicobacter pylori infection previously failed in eradication: A real-world, retrospective clinical study in China.
Gao W; Teng G; Wang C; Xu Y; Li Y; Cheng H
Helicobacter; 2022 Oct; 27(5):e12918. PubMed ID: 35877765
[TBL] [Abstract][Full Text] [Related]
18. Clinical impact of vonoprazan-based dual therapy with amoxicillin for H. pylori infection in a treatment-naïve cohort of junior high school students in Japan.
Gotoda T; Kusano C; Suzuki S; Horii T; Ichijima R; Ikehara H
J Gastroenterol; 2020 Oct; 55(10):969-976. PubMed ID: 32666199
[TBL] [Abstract][Full Text] [Related]
19. Comparison of vonoprazan-based dual therapy with vonoprazan-based bismuth quadruple therapy for treatment-naive patients with Helicobacter pylori infection: A propensity score matching analysis.
Liu Z; Chen X; Sun DJ; Zhao WW; Kou L; Zheng WW; Hao JR; Gao FY
Medicine (Baltimore); 2024 Mar; 103(10):e37476. PubMed ID: 38457567
[TBL] [Abstract][Full Text] [Related]
20. Effectiveness and safety of vonoprazan-based regimens compared with those of proton pump inhibitor (PPI)-based regimens as first-line agents for Helicobacter pylori: a meta-analysis of randomized clinical trials.
Sun Y; Yue L; Hu W
Eur J Clin Pharmacol; 2023 Feb; 79(2):279-288. PubMed ID: 36527456
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]